Norway Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Norway Pharmaceuticals and Healthcare Report

Norway Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Norway Pharmaceuticals and Healthcare Report
Published Oct 01, 2016
65 pages — Published Oct 01, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

In August ----, Norwegian cancer vaccine company Ultimovacs secured NOK--mn (USD-.-mn) to conduct further testing of its cancer vaccine UV-. ...to conduct further testing of its cancer vaccine UV-. As of July ----, Norway-based Navamedic is commencing a new business phase, the first steps of which were marked by the end of its partnership agreement with South Africa-based Aspen Pharmacare (a deal that had secured Navamedic distribution of Aspen products in the Nordic and Benelux markets since ----), and the entering into an eight-year agreement with TopRidge Pharma for the distribution of Imdur (isosorbide mononitrate) in European markets. In line with Norway-based Curida s plan to become a centre for industrialisation of medical innovation, in June ----, Curida signed an agreement with Norwegian biotechnology company PCI Biotech for the production of PCI Biotech main product, Amphinex. ...and is hoped will facilitate rapid access to treatment.

...Obesity boom will substantially increase the non-communicable disease burden. High GDP per-capita will facilitate continued spending on high-value drugs in the medium term. High growth potential for the generic drug market as the government increases its focus on cost containment. The prescription drugs market is expected to remain the dominant segment, as the demand for the latest medicines stays high - as is the norm for Western European countries. Ageing population likely to lead to growing demand for pharmaceuticals for chronic non-communicable conditions, such as Alzheimer s disease and cancer. ...Ageing population likely to lead to growing demand for pharmaceuticals for chronic non-communicable conditions, such as Alzheimer s disease and cancer. The government focus on the development of the biotech and pharmaceutical sector to remain a key policy priority as the economy diversifies away from its dependency on energy exports.

...In line with increasing government efforts to promote the life sciences industry, in September ----, Norway s Research Council announced the launch of grants of up to NOK--mn (USD-.-mn) to support R&D projects in the health sector with the aim of boosting production technology and ensuring that innovation reaches the market and patients (Forskningsradet). ...In line with increasing government efforts to promote the life sciences industry, in September ----, Norway s Research Council announced the launch of grants of up to NOK--mn (USD-.-mn) to support R&D projects in the health sector with the aim of boosting production technology and ensuring that innovation reaches the market and patients (Forskningsradet). According to the latest reported data, Novartis is the top selling company in Norway s pharmaceutical market (as reported in September ----), with sales statistics showing a particular increase in oncology and multiple sclerosis drugs, said Novartis Country Manager Veronika Barrabes to media outlet Dagens ...

  
Source:
Document ID
2052-5052
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Norway Pharmaceuticals and Healthcare Report" Oct 01, 2016. Alacra Store. Dec 07, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Norway-Pharmaceuticals-and-Healthcare-Report-2026-1461>
  
APA:
Business Monitor International - Industry Reports. (2016). Norway Pharmaceuticals and Healthcare Report Oct 01, 2016. New York, NY: Alacra Store. Retrieved Dec 07, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Norway-Pharmaceuticals-and-Healthcare-Report-2026-1461>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.